





		EMLc	ATC codes: <a href="#">J01EE01</a>
Indication	Pneumocystosis	ICD11 code: <a href="#">1F2G.Z</a>	
INN	Sulfamethoxazole + trimethoprim		
Medicine type	Chemical agent		
Antibiotic groups	<a href="#">A ACCESS</a>		
List type	Core (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule ; 80 mg + 16 mg per mL in 10 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid (EMLc) Oral > Solid: 100 mg + 20 mg tablet (EMLc) ; 400 mg + 80 mg tablet (EMLc) ; 800 mg + 160 mg tablet Oral > Solid > dispersible tablet: 100 mg + 20 mg (EMLc)		
EML status history	First added in 1997 ( <a href="#">TRS 882</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2011 ( <a href="#">TRS 965</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Wikipedia	<a href="#">Sulfamethoxazole + trimethoprim</a> 		
DrugBank	<a href="#">Sulfamethoxazole</a>  , <a href="#">Trimethoprim</a> 		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of a new strength formulation of sulfamethoxazole + trimethoprim (dispersible tablet 100 mg + 20 mg) on the EMLc.

